RayKnowChina Research Map
Shortlist0

FuzhouFujian Medical University

First Affiliated Hospital of Fujian Medical University

福建医科大学附属第一医院

Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Fujian Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌17 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
  3. Hepatocellular carcinoma肝细胞癌59 papers led
  4. Stomach cancer胃癌38 papers led1 open trial led
  5. Retinoblastoma视网膜母细胞瘤1 paper led
  6. Osteosarcoma骨肉瘤13 papers led
  7. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  8. Neuroblastoma神经母细胞瘤5 papers led
  9. Multiple myeloma多发性骨髓瘤15 papers led1 open trial led
  10. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led1 open trial led
  11. Beta thalassaemiaβ 地中海贫血0 papers led
  12. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病4 papers led
  13. Myasthenia gravis重症肌无力2 papers led
  14. Wilson disease肝豆状核变性(Wilson 病)3 papers led1 open trial led
  15. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  16. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  17. Amyotrophic lateral sclerosis肌萎缩侧索硬化症6 papers led1 open trial led
  18. Spinal muscular atrophy脊髓性肌萎缩症0 papers led1 open trial led
  19. Duchenne muscular dystrophy杜氏肌营养不良5 papers led1 open trial led
  20. Behçet disease白塞病2 papers led
  21. IgA nephropathyIgA 肾病3 papers led
  22. Primary biliary cholangitis原发性胆汁性胆管炎2 papers led
  23. Primary sclerosing cholangitis原发性硬化性胆管炎2 papers led
  24. Hirschsprung disease先天性巨结肠2 papers led
  25. Hereditary angioedema遗传性血管性水肿0 papers led
  26. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led

Not listed for: Hepatoblastoma, Chordoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 17 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
17
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 3320232024: 5520242025: 442025

5 hospitals in Fuzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIInduction / concurrent chemotherapy
Departments in papersRadiation oncologyENT / head & neck surgeryRadiology / nuclear medicineMedical oncology
Papers it led17
  1. LncRNA ZNF295-AS1 modulates nasopharyngeal carcinoma progression via the miR-762/HDAC6 axis-mediated autophagy.2025Cellular signalling
  2. Deformable registration for nasopharyngeal carcinoma using adaptive mask and weight allocation strategy based CycleFCNs model.2025Radiation oncology (London, England)Free full text
  3. Long-term trends in the burden of nasopharyngeal carcinoma in China: A comprehensive analysis from 1990 to 2021 and projections to 2030 based on the global burden of disease study 2021.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. VMAT with CCC Algorithm Optimizes Trismus Prevention: Dose-Response Analysis of Jaw Muscles Dmean and Dmax in T3-T4 Nasopharyngeal Carcinoma.2025Technology in cancer research & treatmentFree full text
  5. Radiation-induced nasopharyngeal ulcers after re-irradiation with intensity-modulated radiotherapy in locoregional recurrent nasopharyngeal carcinoma patients: a dose-volume-outcome analysis.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  6. A head-to-head comparison of [68Ga]Ga-DOTATATE and [68Ga]Ga-FAPI PET/CT in patients with nasopharyngeal carcinoma: a single-center, prospective study.2024European journal of nuclear medicine and molecular imaging
  7. Polo-like kinase 1 inhibitor NMS-P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities.2024Journal of biochemical and molecular toxicology
  8. The association analysis between fatigue and body composition loss in patients with nasopharyngeal carcinoma during radiotherapy: An observational longitudinal study.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  9. Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function.2024Scientific reportsFree full text
  10. The effect of early oral nutritional supplements on improving nutritional outcomes and radiation-induced oral mucositis for nasopharyngeal carcinoma patients undergoing concurrent chemoradiotherapy.2023Head & neck
  11. Effect of nutritional status before radiotherapy on radiation-induced acute toxicities in patients with nasopharyngeal carcinoma.2023Head & neck
  12. Correlation between hippocampal radiation doses and psychological condition for patients with stage T1-2 nasopharyngeal carcinoma.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  13. The psychological status in patients with nasopharyngeal carcinoma during radiotherapy.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  14. [68Ga]Ga-FAPI PET/CT Improves the T Staging of Patients with Newly Diagnosed Nasopharyngeal Carcinoma: A Comparison with [18F]F-FDG.2022Molecular imaging and biology
  15. Prognostic models for 1-year survival of NPC after radiotherapy in different ages.2021European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  16. Anxiety and depression status prior to radiotherapy in patients with nasopharyngeal carcinoma and its effect on acute radiation toxicities.2021European journal of cancer care
  17. The effect of psychological condition before radiotherapy on prognosis in 390 patients initially treated for nasopharyngeal carcinoma.2021Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
All its trials on ClinicalTrials.gov, any status4
  1. A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective StudyCompletedNCT05990998Lead sponsorPhase 1/Phase 2Start 2022-11
  2. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic ImagesStatus unknownNCT05627310Study siteStart 2022-11
  3. Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal CarcinomaCompletedNCT04823468Study siteN/AStart 2021-07
  4. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02944708Study sitePhase 3Start 2015-10
More papers found outside PubMed (not counted)6
  1. LBA103 Early versus routine oral nutritional supplements during concurrent chemoradiotherapy for nasopharyngeal carcinoma: Efficacy and cost-utility analysis in a multicenter randomized controlled trial2025Annals of Oncologyconference-abstract
  2. Multicenter dosimetric consistency evaluation of IMRT and VMAT techniques based on AAPM TG119 Report and clinical cases2025Radiation Medicine and Protectionarticle
  3. Signal “off-on” electrochemical aptamer sensing of interleukin-6 based on platinum nanoparticles/MIL-88B MOF nanozyme2025Talanta Openarticle
  4. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  5. Identifying immune cell infiltration and diagnostic biomarkers for nasopharyngeal carcinoma through bioinformatic analysis2024Research Squarepreprint
  6. General Introduction of PET/CT of Nasopharyngeal Carcinoma2023Springer eBooksbook-chapter

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 222025

5 hospitals in Fuzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy
Departments in papersMedical oncology
Papers it led3
  1. Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China.2025Expert review of pharmacoeconomics & outcomes research
  2. First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis.2025PloS oneFree full text
  3. LncRNA NRON negatively regulates cisplatin-induced cell apoptosis via downregulating miR-31 in esophageal squamous cell carcinomas.2022In vitro cellular & developmental biology. Animal
All its trials on ClinicalTrials.gov, any status5
  1. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  2. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  3. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  4. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  5. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
More papers found outside PubMed (not counted)11
  1. CircSLC7A5 upregulates NRD1 by competing with miR-148a-3p to promote progression of esophageal squamous cell carcinoma2025Research Squarepreprint
  2. Agaricus blazei murrill and Enteromorpha prolifera-derived polysaccharides gain therapeutic effects on esophageal squamous cell carcinoma2024Journal of Functional Foodsarticle
  3. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  7. Targeting UNC-51-like kinase 1 can inhibit esophageal cancer cell proliferation and regulate autophagy2023Research Squarepreprint
  8. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  9. Association between tea consumption and quality of life in men with esophageal squamous carcinoma based on TTD model2022Research Squarepreprint
  10. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset
  11. Real-world clinical effectiveness and safety of camrelizumab in esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 59 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
59
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 7720212022: 9920222023: 7720232024: 131320242025: 23232025

6 hospitals in Fuzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07391839

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shanghai, Zhengzhou

  2. Recruiting
    Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
    Phase
    Not given
    Started
    2024-08
    Registry
    NCT06561399

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 2 listed hospitals as study sitesFuzhou

  3. Recruiting
    Neoadjuvant Triple Therapy for Resectable HCC
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06569498

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

  4. Recruiting
    Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06602011

    Age 18 years to 75 years (registered criteria)

    Led by Fujian Provincial Hospital; 4 listed hospitals as study sitesFuzhou, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionHepatitis B & cirrhosis
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Medical oncology
Papers it led59
  1. Epigenetic Silencing of SFRP5 Promotes Hepatocellular Carcinoma Progression and Metastasis via Wnt/β-Catenin Signaling.2025APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  2. Decision Fusion Model for Predicting Microvascular Invasion in Hepatocellular Carcinoma Based on Multi-MR Habitat Imaging and Machine-Learning Classifiers.2025Academic radiology
  3. Percutaneous MR-Guided Thermal Ablation for Recurrent Subcentimeter Hepatocellular Carcinoma.2025Academic radiology
  4. Predicting Microvascular Invasion and Early Recurrence in Hepatocellular Carcinoma Using DeepLab V3+ Segmentation of Multiregional MR Habitat Images.2025Academic radiology
  5. Single-cell and bulk transcriptome analysis unveils a ligand-receptor-based signature for prognostication and reveals that TREM1 controls the malignant behaviors of hepatocellular carcinoma.2025Acta biochimica et biophysica SinicaFree full text
  6. Lenvatinib combined with anti-PD-1 antibodies plus locoregional treatment for initial unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter real-world study.2025BMC cancerFree full text
  7. Refining MR-guided thermal ablation for HCC within the Milan criteria: a decade of clinical outcomes and predictive modeling at a single institution.2025BMC cancerFree full text
  8. HRAS Induces Ferroptosis through Upregulating HSPB1 in Hepatocellular Carcinoma.2025Combinatorial chemistry & high throughput screening
  9. CDK4 as a Prognostic Marker of Hepatocellular Carcinoma and CDK4 Inhibitors as Potential Therapeutics.2025Current medicinal chemistryFree full text
  10. Intratumoral Microbe Correlated with Expression of DNA Methylation Genes in Hepatocellular Carcinoma.2025Digestive diseases and sciencesFree full text
  11. E2F2/MUC1 Enhances Cell Stemness of Hepatocellular Carcinoma by Regulating the Notch Signaling Pathway.2025Digestive diseases and sciences
  12. Tumor suppressor OSR1 is modified by SUMO1 and regulates the Wnt/β-catenin signaling pathway in HCC.2025Experimental cell research
  13. Utilization of artificial circular RNAs as miRNA sponges and anti-PD-1 scFv expression platforms to suppress hepatocellular carcinoma progression.2025Frontiers in immunologyFree full text
  14. The diagnostic value of hepatitis B core-related antigen in occult hepatitis B virus infection and its related hepatocellular carcinoma.2025International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  15. Predictive Value of Peripheral Blood Follicular Helper T Cells for Short-term Prognosis in Patients with Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.2025Iranian journal of allergy, asthma, and immunology
  16. An analysis of the clinical efficacy and safety of a temperature-sensitive liquid embolic agent loaded with lobaplatin for the treatment of unresectable primary hepatocellular carcinoma through chemoembolization.2025Journal of cancer research and therapeutics
  17. The Efficacy and Safety of TACE or HAIC Combined With ICIs and Angiogenesis Inhibitors in Unresectable Hepatocellular Carcinoma.2025Journal of immunotherapy (Hagerstown, Md. : 1997)
  18. A Nomogram Based on MRI Visual Decision Tree to Evaluate Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.2025Journal of magnetic resonance imaging : JMRIFree full text
  19. A CCR5 antagonist enhances the radiosensitivity of hepatocarcinoma in a mouse model.2025Journal of radiation researchFree full text
  20. MR-Guided Microwave Ablation for Patients with Cirrhosis Complicated by Small Hepatocellular Carcinoma.2025Journal of vascular and interventional radiology : JVIR
  21. Computed tomography radiomics prediction of survival in hepatocellular carcinoma and is associated with ADH1A expression of the retinol metabolism pathway.2025MedicineFree full text
  22. Construction and validation of a novel model for guiding targeted combined immunotherapy in advanced hepatocellular carcinoma.2025Scientific reportsFree full text
  23. Machine learning analysis identified NNMT as a potential therapeutic target for hepatocellular carcinoma based on PCD-related genes.2025Scientific reportsFree full text
  24. Delta-radiomics Analysis Based on Multi-phase Contrast-enhanced MRI to Predict Early Recurrence in Hepatocellular Carcinoma After Percutaneous Thermal Ablation.2024Academic radiology
  25. Prognostic value of FDX1, the cuprotosis key gene, and its prediction models across imaging modalities and histology.2024BMC cancerFree full text
  26. A novel super-enhancer-related risk model for predicting prognosis and guiding personalized treatment in hepatocellular carcinoma.2024BMC cancerFree full text
  27. Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants.2024Cancer immunology, immunotherapy : CIIFree full text
  28. Long non-coding RNAFOXD1-AS1 modulated CTCs epithelial-mesenchymal transition and immune escape in hepatocellular carcinoma in vitro by sponging miR-615-3p.2024Cancer reports (Hoboken, N.J.)Free full text
  29. Detection of serum large and middle hepatitis B virus surface proteins: A novel potential diagnostic and prognostic biomarker for chronic hepatitis B.2024Clinica chimica acta; international journal of clinical chemistry
  30. ARHGEF39 targeted by E2F1 fosters hepatocellular carcinoma metastasis by mediating fatty acid metabolism.2024Clinics and research in hepatology and gastroenterology
  31. Monocyte distribution width as a promising biomarker for differential diagnosis of chronic hepatitis, cirrhosis, and hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  32. Atezolizumab Plus Bevacizumab Versus Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2024Journal of clinical pharmacology
  33. Clinical-Radiologic Morphology-Radiomics Model on Gadobenate Dimeglumine-Enhanced MRI for Identification of Highly Aggressive Hepatocellular Carcinoma: Temporal Validation and Multiscanner Validation.2024Journal of magnetic resonance imaging : JMRI
  34. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.2024Scientific reportsFree full text
  35. Novel nomograms based on microvascular invasion grade for early-stage hepatocellular carcinoma after curative hepatectomy.2024Scientific reportsFree full text
  36. Metabolic dysfunction-associated fatty liver disease increases the risk of complications after radical resection in patients with hepatocellular carcinoma.2024World journal of surgical oncologyFree full text
  37. LI-RADS category 3, 4, and M observations: a multiple parameters diagnostic model for hepatocellular carcinoma.2023Acta radiologica (Stockholm, Sweden : 1987)
  38. Prognostic implications of alpha-fetoprotein and C-reactive protein elevation in hepatocellular carcinoma following resection (PACE): a large cohort study of 2770 patients.2023BMC cancerFree full text
  39. Emerging roles of bile acids in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.2023Cellular & molecular immunologyFree full text
  40. The effect of adjuvant transarterial chemoembolization for hepatocellular carcinoma after liver resection based on risk stratification.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  41. The impact of metabolic dysfunction-associated fatty liver disease on the prognosis of patients with hepatocellular carcinoma after radical resection.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  42. Development and validation of a diagnostic model for AFP-negative hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  43. ATP13A2 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Hepatocellular Carcinoma.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  44. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M.2022Abdominal radiology (New York)
  45. Deubiquitinating enzyme JOSD2 promotes hepatocellular carcinoma progression through interacting with and inhibiting CTNNB1 degradation.2022Cell biology international
  46. Compartmentalisation of Hepatitis B virus X gene evolution in hepatocellular carcinoma microenvironment and the genotype-phenotype correlation of tumorigenicity in HBV-related patients with hepatocellular carcinoma.2022Emerging microbes & infectionsFree full text
  47. Adenosine Triphosphate in Serum as a Promising Biomarker for Differential Diagnosis of Hepatitis B Disease Progression.2022Frontiers in immunologyFree full text
  48. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.2022Journal of cancer research and clinical oncologyFree full text
  49. Emerging role of mitochondria in response to HBV infection.2022Journal of clinical laboratory analysisFree full text
  50. A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma.2022PloS oneFree full text
  51. Pembrolizumab associated Stevens-Johnson syndrome with porokeratosis in a patient in the setting of primary hepatocellular carcinoma.2022The Australasian journal of dermatology
  52. Radiomic analysis based on multi-phase magnetic resonance imaging to predict preoperatively microvascular invasion in hepatocellular carcinoma.2022World journal of gastroenterologyFree full text
  53. A radiomics nomogram based on contrast-enhanced MRI for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma.2021Abdominal radiology (New York)
  54. Tumor Microenvironment Triggered Cascade-Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma.2021Advanced healthcare materials
  55. FAM83G promotes proliferation, invasion, and metastasis by regulating PI3K/AKT signaling in hepatocellular carcinoma cells.2021Biochemical and biophysical research communications
  56. IL-17 and IL-21 polymorphisms in relation to HBV related hepatocellular carcinoma in Chinese Han population.2021Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  57. Development of pre and post-operative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma.2021Liver international : official journal of the International Association for the Study of the Liver
  58. [Retracted] Anticancer and apoptotic activities of oleanolic acid are mediated through cell cycle arrest and disruption of mitochondrial membrane potential in HepG2 human hepatocellular carcinoma cells.2021Molecular medicine reportsFree full text
  59. Downregulation of triggering receptor expressed on myeloid cells 1 inhibits invasion and migration of liver cancer cells by mediating macrophage polarization.2021Oncology reports
Chinese-language papers (not in the count)2
  1. [Research progress of long-chain non-coding RNA in lipid metabolism reprogramming in primary hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Research progress of non-coding RNA-encoding polypeptides in primary hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status12
  1. A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCCStatus unknownNCT06003673Lead sponsorPhase 4Start 2023-07
  2. MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.RecruitingNCT07391839Study sitePhase 1Start 2025-08
  3. Neoadjuvant Triple Therapy for Resectable HCCRecruitingNCT06569498Study siteStart 2024-09
  4. Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)RecruitingNCT06561399Study siteStart 2024-08
  5. Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)RecruitingNCT06602011Study siteStart 2024-09
  6. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  7. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  8. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  9. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  10. To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With Primary Liver CancerTerminatedNCT04520906Study siteN/AStart 2020-12
  11. Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma HugeStatus unknownNCT03277716Study siteN/AStart 2017-12
  12. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 38 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.4%.

Papers led
38
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 3320222023: 101020232024: 101020242025: 772025

6 hospitals in Fuzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06791083

    Age 18 years to 75 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryImaging & AIPeritoneal spread & advanced disease
Departments in papersGastroenterology / hepatologyRadiology / nuclear medicineMedical oncologyPathology / laboratory medicine
Papers it led38
  1. Deciphering the Risk of Developing Lung Cancer after the Diagnosis of Gastric Cancer with Genetic Evidence: A European and East Asian Populations-Based Mendelian Randomization Analysis.2026Cancer research and treatmentFree full text
  2. Short-term and long-term efficacy of laparoscopic D2 lymphadenectomy combined with complete mesogastrium excision for locally advanced upper gastric cancer.2026Surgery
  3. Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: a two-center retrospective cohort study.2025BMC gastroenterologyFree full text
  4. Dual-layer spectral detector CT-based scoring system for noninvasive TP53 expression assessment and adjuvant chemotherapy response prediction in gastric cancer: a multicenter cross-sectional study.2025International journal of surgery (London, England)Free full text
  5. Taichunamide-A Inhibits Stomach Cancer Growth Through AKT/MAPK Pathway Suppression and EGFR Inhibitor Synergy.2025Journal of biochemical and molecular toxicology
  6. Novel m5C-dependent post-transcriptional regulation of KIF11 drives lymphatic metastasis in gastric cancer.2025Scientific reportsFree full text
  7. YY1-mediated transcriptional regulation of LINC01615 inhibits WNT2 mRNA degradation to promote gastric cancer progression.2025Scientific reportsFree full text
  8. PPM1B degradation mediated by TRIM25 ubiquitination modulates cell cycle and promotes gastric cancer growth.2025Scientific reportsFree full text
  9. New classification of gastric polyps: An in-depth analysis and critical evaluation.2025World journal of gastroenterologyFree full text
  10. ASO Author Reflections: A Multicenter Retrospective Study on the Clinical and Prognostic Value of Tumor Deposits in Advanced Gastric Cancer.2024Annals of surgical oncology
  11. Correlation Analysis Between Tumor Deposit and Clinicopathologic Characteristics and Prognosis of Gastric Cancer: A Multicenter Retrospective Study.2024Annals of surgical oncology
  12. The effect of supplementary parenteral nutrition with different energy intakes on clinical outcomes of patients after gastric cancer surgery.2024BMC surgeryFree full text
  13. Modulation of YBX1-mediated PANoptosis inhibition by PPM1B and USP10 confers chemoresistance to oxaliplatin in gastric cancer.2024Cancer letters
  14. NAT10 Phase Separation Regulates YTHDF1 Splicing to Promote Gastric Cancer Progression.2024Cancer research
  15. Comments on "Novel strategy of hold-and-drag clip closure with mantis-like claw for post-gastric endoscopic submucosal dissection defect of <30 mm".2024Endoscopy
  16. Bioinformatics Analysis Reveals Prognostic Significance of the Macrophage Marker Gene Signature in Gastric Adenocarcinoma.2024Frontiers in bioscience (Landmark edition)
  17. The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.2024PharmacogenomicsFree full text
  18. Curcumin derivative C210 induces Epstein-Barr virus lytic cycle and inhibits virion production by disrupting Hsp90 function.2024Scientific reportsFree full text
  19. Super-enhancer-driven ZFP36L1 promotes PD-L1 expression in infiltrative gastric cancer.2024eLifeFree full text
  20. Integrated bioinformatics analysis for conducting a prognostic model and identifying immunotherapeutic targets in gastric cancer.2023BMC bioinformaticsFree full text
  21. Evaluation of vital genes correlated with CD8 + T cell infiltration as prognostic biomarkers in stomach adenocarcinoma.2023BMC gastroenterologyFree full text
  22. Sex-specific disparities of serum pepsinogen I in relation to body mass index.2023Clinical chemistry and laboratory medicine
  23. Impact of PIWIL1 Single Nucleotide Polymorphisms on Gastric Cancer Risk in a Chinese Population.2023Genetic testing and molecular biomarkers
  24. Association of Malnutrition Diagnosed Using Global Leadership Initiative on Malnutrition Criteria with Severe Postoperative Complications After Gastrectomy in Patients with Gastric Cancer.2023Journal of laparoendoscopic & advanced surgical techniques. Part A
  25. Pretreatment controlling nutritional status (CONUT) score and carcinoembryonic antigen level provide tumor progression and prognostic information in gastric cancer: A retrospective study.2023MedicineFree full text
  26. The short- and long-term effect of laparoscopic total gastrectomy in D2 radical treatment combined with spleno-pancreatectomy under membrane anatomy.2023Surgical endoscopy
  27. The short- and long-term effect of membrane anatomy-guided laparoscopic D2 lymphadenectomy plus regional complete mesogastrium excision for locally advanced gastric cancer.2023Surgical endoscopy
  28. Short and Long-term Efficacy of 3-dimensional Laparoscopic-assisted D2 Radical Gastrectomy Under the Guidance of Membrane Anatomy for Locally Advanced Gastric Cancer.2023Surgical laparoscopy, endoscopy & percutaneous techniques
  29. Transcriptome sequencing and miRNA-mRNA network construction in exosome of macrophage M2 in stomach adenocarcinoma.2023World journal of surgical oncologyFree full text
  30. Prognostic value of long-term antidiabetic and antihypertensive therapy in postoperative gastric cancer patients: the FIESTA study.2022BMC gastroenterologyFree full text
  31. The effects of nutritional support team intervention on postoperative immune function, nutritional statuses, inflammatory responses, clinical outcomes of elderly patients with gastric cancer.2022BMC surgeryFree full text
  32. [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT.2022European journal of nuclear medicine and molecular imaging
  33. Transcription factor KLF15 inhibits the proliferation and migration of gastric cancer cells via regulating the TFAP2A-AS1/NISCH axis.2021Biology directFree full text
  34. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  35. Widespread Metastatic Gastric Signet-Ring Cell Carcinoma Shown by 68Ga-FAPI PET/CT.2021Clinical nuclear medicine
  36. Genetic variants of autophagy-related genes in the PI3K/Akt/mTOR pathway and risk of gastric cancer in the Chinese population.2021Gene
  37. Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use.2021Journal of cellular and molecular medicineFree full text
  38. Effect of single-incision laparoscopic distal gastrectomy guided by ERAS and the influence on immune function.2021World journal of surgical oncologyFree full text
Chinese-language papers (not in the count)1
  1. [FTO mRNA expression level in gastric cancer tissues and its relationship with clinicopathological parameters and prognosis].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
All its trials on ClinicalTrials.gov, any status5
  1. Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric CancerRecruitingNCT06791083Lead sponsorPhase 2Start 2024-06
  2. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaCompletedNCT06585501Study siteStart 2024-08
  3. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  4. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  5. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

3 hospitals in Fuzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 13 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 2220222023: 0020232024: 0020242025: 332025

13 hospitals in Fuzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Over half of these papers are lab or animal studies.

Papers it led13
  1. Licochalcone B targets neural cell adhesion molecule 1 to inhibit osteosarcoma progression and ferroptosis resistance via extracellular signal-regulated kinase 5 and nuclear factor kappa B pathways.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  2. The integrin α2-osteoclast axis: a key driver of bone destruction and therapeutic target in osteosarcoma.2025Journal of translational medicine
  3. Guggulsterone suppresses osteosarcoma progression by inhibiting glycolysis through MAPK signaling pathway.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  4. Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K/AKT and MAPK pathways.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  5. Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.2022International journal of nanomedicine
  6. Generation and characterization of patient-derived xenografts from patients with osteosarcoma.2022Tissue & cell
  7. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway.2021Acta biochimica et biophysica Sinica
  8. Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma.2021Acta biochimica et biophysica Sinica
  9. KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.2021Biochemical and biophysical research communications
  10. MicroRNA-1287-5p promotes ferroptosis of osteosarcoma cells through inhibiting GPX4.2021Free radical research
  11. Inhibition of BUB1 suppresses tumorigenesis of osteosarcoma via blocking of PI3K/Akt and ERK pathways.2021Journal of cellular and molecular medicine
  12. Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma.2021Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  13. Clinicopathological and prognostic value of NADPH oxidase 2 (NOX2) in primary osteosarcoma.2021Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
Chinese-language papers (not in the count)2
  1. [Reconstruction of bone defects after resection of osteosarcoma in children with artificial hemi-knee prosthesis].2025Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  2. [Bioinformatics analysis of differently expressed genes in osteoblastic sarcoma and screening of key genes].2022Zhonghua zhong liu za zhi [Chinese journal of oncology]
Earlier papers (2016–2020)12
  1. HER4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway.2020Acta biochimica et biophysica Sinica
  2. Long non-coding RNA LINC00426 contributes to doxorubicin resistance by sponging miR-4319 in osteosarcoma.2020Biology direct
  3. Synthesis and Application of a Long-Circulating Radiolabeled Peptide for Targeting of Osteosarcoma.2020Molecular imaging and biology
  4. ACTN4 Promotes the Proliferation, Migration, Metastasis of Osteosarcoma and Enhances its Invasive Ability through the NF-κB Pathway.2020Pathology oncology research : POR
  5. [Treatment and influencing factors of infection after limb salvage surgery for malignant tumor around knee joint].2020Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  6. A Nanodrug Consisting Of Doxorubicin And Exosome Derived From Mesenchymal Stem Cells For Osteosarcoma Treatment In Vitro.2019International journal of nanomedicine
  7. Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma.2019Scandinavian journal of clinical and laboratory investigation
  8. Clinicopathological and prognostic values of fibronectin and integrin αvβ3 expression in primary osteosarcoma.2019World journal of surgical oncology
  9. miR-219a-5p represses migration and invasion of osteosarcoma cells via targeting EYA2.2018Artificial cells, nanomedicine, and biotechnology
  10. Comparative proteomics of cancer stem cells in osteosarcoma using ultra-high-performance liquid chromatography and Orbitrap Fusion mass spectrometer.2018Talanta
  11. Transdifferentiation of human MNNG/HOS osteosarcoma cells into vascular endothelial cells in vitro and in vivo.2017Oncology reports
  12. Verification of TREX1 as a promising indicator of judging the prognosis of osteosarcoma.2016Journal of orthopaedic surgery and research

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

6 hospitals in Fuzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 5 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

9 hospitals in Fuzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 15 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.9%.

Papers led
15
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 4420232024: 5520242025: 332025

2 hospitals in Fuzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
    Phase
    Early phase 1
    Started
    2020-08
    Registry
    NCT04504526

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

  2. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  3. Recruiting
    Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-05
    Registry
    NCT06375044

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Nanjing, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance
Departments in papersRadiology / nuclear medicineMedical oncologyOphthalmology / neuro-ophthalmology
Papers it led15
  1. Global burden and trends of multiple myeloma attributable to high body mass index: a comprehensive analysis of the global burden of disease 2021 study with projections to 2040.2025BMC public healthFree full text
  2. The value of multiparametric functional MRI histogram features in assessing multiple myeloma activity.2025European radiology
  3. B4GALT3 as a Key Glycosyltransferase Gene in Multiple Myeloma Progression: Insights From Bioinformatics, Machine Learning, and Experimental Validation.2025Molecular carcinogenesis
  4. Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.2024Cancer letters
  5. NCX1/Ca2+ promotes autophagy and decreases bortezomib activity in multiple myeloma through non-canonical NFκB signaling pathway.2024Cell communication and signaling : CCSFree full text
  6. [68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT.2024European journal of nuclear medicine and molecular imaging
  7. Role of BACH1 in multiple myeloma.2024Hematology (Amsterdam, Netherlands)
  8. SSBP1 is a novel prognostic marker and promotes disease progression via p38MAPK signaling pathway in multiple myeloma.2024Molecular carcinogenesis
  9. Retrospective Analysis of the Expression of CD56 in Multiple Myeloma with Bone-Related Extramedullary Diseases.2023Annals of clinical and laboratory science
  10. Metformin attenuates multiple myeloma cell proliferation and encourages apoptosis by suppressing METTL3-mediated m6A methylation of THRAP3, RBM25, and USP4.2023Cell cycle (Georgetown, Tex.)Free full text
  11. NCX1 disturbs calcium homeostasis and promotes RANKL-induced osteoclast differentiation by regulating JNK/c-Fos/NFATc1 signaling pathway in multiple myeloma.2023Clinical and experimental medicineFree full text
  12. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.2023Mini reviews in medicinal chemistry
  13. NBR2/miR-561-5p/DLC1 axis inhibited the development of multiple myeloma by activating the AMPK/mTOR pathway to repress glycolysis.2022Neoplasma
  14. Pathophysiological role of calcium channels and transporters in the multiple myeloma.2021Cell communication and signaling : CCSFree full text
  15. Regulatory role of DEPTOR‑mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma.2021International journal of molecular medicineFree full text
Chinese-language papers (not in the count)2
  1. [Correlation between Serum Interleukin-33, β2-Microglobulin Levels and DS Stage in Patients with Multiple Myeloma].2023Zhongguo shi yan xue ye xue za zhi
  2. [Effect of γδ T cells on the Proliferation, Apoptosis and Autophagy of Multiple Myeloma Cells].2022Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status4
  1. Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative DiseasesRecruitingNCT04504526Lead sponsorEarly phase 1Start 2020-08
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Study sitePhase 1Start 2024-05
  4. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Fuzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07491263

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic LeukemiaNot yet recruitingNCT07491263Lead (inferred)Phase 1Start 2026-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Fuzhou for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 4 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 002025

1 hospital in Fuzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisAcute attack treatment
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

2 hospitals in Fuzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStandard immunotherapyThymus & thymectomy
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Wilson disease

肝豆状核变性(Wilson 病)

Led 3 of the 201 English-language PubMed papers on Wilson disease with an author in mainland China, 2021–2025: 1.5%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 002025

1 hospital in Fuzhou for Wilson disease28 hospitals in China for Wilson disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Registered Cohort Study on Wilson's Disease
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT04012658

    Age not stated (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGenetics (ATP7B)Brain & movement symptomsDiagnosis & copper tests
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

2 hospitals in Fuzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Fuzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology
Papers it led1
  1. Multi-Omics Analysis Links Mitochondrial-Related Genes to Idiopathic Pulmonary Fibrosis and In Vivo Transcriptome Validation.2025Translational research : the journal of laboratory and clinical medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 6 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.8%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 222025

5 hospitals in Fuzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Registered Cohort Study on Amyotrophic Lateral Sclerosis
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT04008329

    Age not stated (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology
Papers it led6
  1. Research advances in dysphagia animal models.2025Animal models and experimental medicine
  2. Biomarker profile of a Chinese ALS cohort: A comprehensive clinical-biomarkers-imaging analysis.2025Neurobiology of disease
  3. Detection of pTDP-43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis.2024Brain pathology (Zurich, Switzerland)
  4. Alterations in nasal microbiota of patients with amyotrophic lateral sclerosis.2024Chinese medical journal
  5. Peak expiratory flow is a reliably household pulmonary function parameter correlates with disease severity and survival of patients with amyotrophic lateral sclerosis.2022BMC neurology
  6. Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosis.2021Annals of clinical and translational neurology
Earlier papers (2016–2020)4
  1. Promoting identification of amyotrophic lateral sclerosis based on label-free plasma spectroscopy.2020Annals of clinical and translational neurology
  2. Identification and functional analysis of novel mutations in the SOD1 gene in Chinese patients with amyotrophic lateral sclerosis.2019Amyotrophic lateral sclerosis & frontotemporal degeneration
  3. Prognostic analysis of amyotrophic lateral sclerosis based on clinical features and plasma surface-enhanced Raman spectroscopy.2019Journal of biophotonics
  4. High frequency of the TARDBP p.M337 V mutation among south-eastern Chinese patients with familial amyotrophic lateral sclerosis.2018BMC neurology
All its trials on ClinicalTrials.gov, any status2
  1. A Registered Cohort Study on Amyotrophic Lateral SclerosisRecruitingNCT04008329Lead sponsorStart 2019-07
  2. An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALSActive, not recruitingNCT06454682Study siteEarly phase 1Start 2023-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Fuzhou for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Registered Cohort Study on SMA
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT04010604

    Age 1 week to 70 years (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)3
  1. Is there cervical spine muscle weakness in patients with Hirayama disease? A morphological study about cross-sectional areas of muscles on MRI.2020European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  2. A 34-Year-Old Female Patient with Hirayama Disease Complicated by Severe Spinal Cord Injury.2019World neurosurgery
  3. Anterior Cervical Surgery for the Treatment of Hirayama Disease.2019World neurosurgery
All its trials on ClinicalTrials.gov, any status3
  1. Antisense Oligonucleotide for Spinal Muscular AtrophyStatus unknownNCT05187260Lead sponsorStart 2022-01
  2. A Registered Cohort Study on SMARecruitingNCT04010604Lead (inferred)Start 2019-07
  3. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 5 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 2.4%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 2220242025: 002025

3 hospitals in Fuzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Registered Cohort Study on Duchenne Muscular Dystrophy
    Phase
    Not given
    Started
    2019-07
    Registry
    NCT04012671

    Age 2 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Fujian Medical UniversityFuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurology

Over half of these papers are lab or animal studies.

Papers it led5
  1. enOsCas12f1-mediated exon skipping for Duchenne muscular dystrophy therapy in humanized mouse model.2024Journal of genetics and genomics = Yi chuan xue bao
  2. Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model.2024Nature communications
  3. CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy.2022Gene therapy
  4. Generation and characterization of an induced pluripotent stem cell line (FJMUNi001-A) from a patient with Duchenne muscular dystrophy carrying c.4518 + 512 T > A variant in the DMD gene.2022Stem cell research
  5. Establishment of a human iPSC line XMDYYYi001-A from a patient with Becker muscular dystrophy harboring duplications of exons 2-19 in dystrophin gene.2021Stem cell research
Earlier papers (2016–2020)2
  1. Cryptic exon activation causes dystrophinopathy in two Chinese families.2020European journal of human genetics : EJHG
  2. Clinical and mutational characteristics of Duchenne muscular dystrophy patients based on a comprehensive database in South China.2017Neuromuscular disorders : NMD
All its trials on ClinicalTrials.gov, any status3
  1. A Registered Cohort Study on Duchenne Muscular DystrophyRecruitingNCT04012671Lead (inferred)Start 2019-07
  2. A Natural History Study In Chinese Male Patients With Duchenne Muscular DystrophyCompletedNCT03760029Study siteN/AStart 2019-07
  3. Long-Term Outcomes of Ataluren in Duchenne Muscular DystrophyCompletedNCT03179631Study sitePhase 3Start 2017-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

3 hospitals in Fuzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 3 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.4%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

4 hospitals in Fuzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 2 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

4 hospitals in Fuzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 2 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 2.0%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

2 hospitals in Fuzhou for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 2 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

5 hospitals in Fuzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led2
  1. CHA-based microarray with Cas12a universal readout for multiple microRNA detection.2025Mikrochimica acta
  2. 10-year experience with single-site laparoscopic-assisted Soave operation for Hirschsprung disease.2025Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Fuzhou for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Fuzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

福建医科大学附属第一医院

First Affiliated Hospital of Fujian Medical University

福州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Binhai Campus of the First Affiliated Hospital; First Affiliated Hospital of Xiamen University; Longyan First Affiliated Hospital of Fujian Medical University; Binhai Branch of the First Affiliated Hospital

Suggest a correctionDownload the data